Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Cancer Chemotherapy and Pharmacology
|
June 3, 2004
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies
Warren A Chow, Timothy W Synold, Merry L Tetef, et al.
Cancer
|
December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Scott M Schuetze, J Kyle Wathen, David R Lucas, et al.
JAMA Oncology
|
May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Scott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Cancer
|
May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study
Alberto S Pappo, Gilles Vassal, John J Crowley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Cancer
|
October 4, 2016
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
Scott M Schuetze, Vanessa Bolejack, Edwin Choy, et al.
Nature Communications
|
September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Journal for Immunotherapy of Cancer
|
October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
The New England Journal of Medicine
|
March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P Patel, Megan Othus, Yuanbin Chen, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Cancer Chemotherapy and Pharmacology
|
June 3, 2004
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies
Warren A Chow, Timothy W Synold, Merry L Tetef, et al.
Cancer
|
December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Scott M Schuetze, J Kyle Wathen, David R Lucas, et al.
JAMA Oncology
|
May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Scott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Cancer
|
May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study
Alberto S Pappo, Gilles Vassal, John J Crowley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Cancer
|
October 4, 2016
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
Scott M Schuetze, Vanessa Bolejack, Edwin Choy, et al.
Nature Communications
|
September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Journal for Immunotherapy of Cancer
|
October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
The New England Journal of Medicine
|
March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P Patel, Megan Othus, Yuanbin Chen, et al.
Page
of 4